Serum Levels of IL-10 and IL-22 Cytokines in Patients with Psoriasis.

BACKGROUND As a chronic inflammatory condition, psoriasis results from an interaction between genetic and immunologic factors in a predisposing environment. In spite of compelling evidence for the role of T cells and cytokines in psoriasis, interleukin (IL)-10 and IL-22 have not been sufficiently investigated. OBJECTIVE To assess the serum levels of IL-10 and IL-22 in patients with psoriasis compared to healthy controls. METHODS A total of 28 patients with psoriasis were compared with 28 age and sex-matched healthy subjects. Psoriasis Area and Severity Index (PASI) criteria were used to measure the severity of the disease. Serum levels of IL-10 and IL-22 were measured in both groups and compared. RESULTS The mean serum level of IL-10 was 89.5±18.7 in patients compared to 117.2±23.4 pg/ml in the controls (p=0.36). Also, serum level of IL-22 was 284.1±49.7 in patients versus 425.4±82.8 pg/ml in control group (p=0.17). There was a significant direct correlation between levels of IL-10 and IL-22 in patients group (p=0.0005). The clinical severity of psoriasis was significantly correlated with high levels of IL-22 (p<0.0001). CONCLUSION The direct correlation between higher levels of IL-22 and disease severity supports the clinical implication of this cytokine in psoriasis.

[1]  M. Netea,et al.  Proinflammatory cytokine responses in patients with psoriasis , 2014, European Cytokine Network.

[2]  G. Chodorowska,et al.  Serum Levels of Selected Th17 and Th22 Cytokines in Psoriatic Patients , 2013, Disease markers.

[3]  Jie Hao,et al.  Targeting Interleukin-22 in Psoriasis , 2013, Inflammation.

[4]  S. Zheng,et al.  Emerging role of interleukin-22 in autoimmune diseases. , 2013, Cytokine & growth factor reviews.

[5]  A. Pietrzak,et al.  Cytokine network in psoriasis revisited. , 2011, European cytokine network.

[6]  J. Bhattacharjee,et al.  Serum Cytokine Profile in Psoriasis-A Case–Control Study in a Tertiary Care Hospital from Northern India , 2011, Indian Journal of Clinical Biochemistry.

[7]  R. Sabat,et al.  Research in practice: IL‐22 and IL‐20: significance for epithelial homeostasis and psoriasis pathogenesis , 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[8]  E Glowacka,et al.  IL-8, IL-12 and IL-10 cytokines generation by neutrophils, fibroblasts and neutrophils- fibroblasts interaction in psoriasis. , 2010, Advances in medical sciences.

[9]  R. Flavell,et al.  IL‐22 and inflammation: Leukin' through a glass onion , 2008, European journal of immunology.

[10]  R. Rizzo,et al.  Soluble human leukocyte antigen-G and interleukin-10 levels in plasma of psoriatic patients: preliminary study on a possible correlation between generalized immune status, treatments and disease , 2008, Archives of Dermatological Research.

[11]  W. Gulliver.  Long‐term prognosis in patients with psoriasis , 2008, The British journal of dermatology.

[12]  Jan Kremláček,et al.  Serum levels of the pro‐inflammatory cytokine interleukin‐12 and the anti‐inflammatory cytokine interleukin‐10 in patients with psoriasis treated by the Goeckerman regimen , 2008, International journal of dermatology.

[13]  Steven R Feldman,et al.  Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. , 2008, Journal of the American Academy of Dermatology.

[14]  Hani A Al-Shobili,et al.  IL-10 implications in psoriasis. , 2008, International journal of health sciences.

[15]  F. Morel,et al.  A role for T cell‐derived interleukin 22 in psoriatic skin inflammation , 2007, Clinical and experimental immunology.

[16]  D. Mcgibbon,et al.  Rook's Textbook of Dermatology, 7th edition , 2006 .

[17]  E. Petinaki,et al.  Evaluation of cytokine serum levels in patients with plaque-type psoriasis. , 2005, International journal of clinical pharmacology research.

[18]  Steven R Feldman,et al.  A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. , 2004, Dermatology online journal.

[19]  A. Mamelak,et al.  The role of interleukin 10 in the pathogenesis and potential treatment of skin diseases. , 2004, Journal of the American Academy of Dermatology.

[20]  F. Kerdel,et al.  Short Communication Mediators of Inflammation, 12(5), 309 /313 (October 2003) BACKGROUND: Psoriatic plaques have been shown to , 2022 .

[21]  A. Robert,et al.  Andrew's Diseases of the Skin , 2002 .

[22]  K. Asadullah,et al.  Interleukin-10 in cutaneous disorders: implications for its pathophysiological importance and therapeutic use , 1999, Archives of Dermatological Research.

[23]  W Sterry,et al.  IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. , 1998, The Journal of clinical investigation.